We have seen an increase in both Zubsolv scripts and tablets market share as well as an increase in the overall market according to this week’s numbers from Wolters Kluwer. Zubsolv tablets market share (4-week rolling average) increased by 0.01 percentage points from last week, reaching 6.51%. TRx market share (4-week rolling average) rose by 0.02 percentage points and totalled 6.10%. The overall market (buprenorphine/naloxone products) in unit sales y/y grew by 7.9% (4-week rolling average ). TRx shows a y/y growth by 8.7% (4-week rolling average).